Trials / Withdrawn
WithdrawnNCT01510561
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
90Y-hPAM4 is administered weekly for 3 weeks combined with 4 weekly doses of gemcitabine to assess. This is a dose escalation study of 90Y-hPAM4 to assess which dose is safe and effective as 3rd line treatment for patients with metastatic pancreatic cancer. Patients are then followed weekly for 12 weeks and afterwards for up to 1 year.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 90Y-hPAM4 | 90Y-hPAM4 will be administered weekly for 3 weeks in conjunction with gemcitabine which will be administered weekly x 4. |
| DRUG | 90Y-hPAM4 | |
| DRUG | 90Y-hPAM4 + gemcitabine |
Timeline
- Start date
- 2012-03-01
- Primary completion
- 2015-06-01
- Completion
- 2015-09-01
- First posted
- 2012-01-16
- Last updated
- 2021-08-19
Locations
24 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01510561. Inclusion in this directory is not an endorsement.